Skip to main content

Beneficial ownership — 13D / 13G

87,339 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
Stephen Evans-Freke ADCT ADC Therapeutics SA 13D/A 2.7% 2y
EMINENCE CAPITAL, LP ASH Ashland Inc. 13D/A 6.4% 2y
BW Group Limited DHT DHT Holdings, Inc. 13D/A 14.9% 2y
BROWNING WEST LP GIL Gildan Activewear Inc. 13D/A 5% 2y
Fairmount Funds Management LLC SYRE Spyre Therapeutics, Inc. 13D/A 11.17% 2y
Fund 1 Investments, LLC CTRN Citi Trends Inc 13D/A 22% 2y
Randa Duncan Williams EPD Enterprise Products Partners L.P. 13D/A 32.3% 2y
Charles W. Riley, Jr., solely in his capacity as the successor trustee of the Everett W. Nordstrom Trust fbo AEG created under the will of Everett W. Nordstrom dated April 1, 1971, and as a successor co-trustee of the Frances W. Nordstrom Trust fbo BAN created under the will of Frances W. Nordstrom dated April 4, 1984. JWN Nordstrom, Inc. 13D 7.62% 2y
Joseph Reda GWAV Greenwave Technology Solutions, Inc. 13G/A 5.68% 2y
WOLVERINE ASSET MANAGEMENT LLC DIST Distoken Acquisition Corporation Ordinary Shares 13G/A 4.57% 2y
Millennium Management LLC MYGN Myriad Genetics Inc 13G 4.97% 2y
Paresh Patel HCI HCI Group, Inc. 13D/A 14.77% 2y
Bain Capital Life Sciences Opportunities III, LP IPSC Century Therapeutics, Inc. 13G 6.6% 2y
FiSai Fund I HoldCo Limited Partnership AYRWF Ayr Wellness Inc. 13G 8.4% 2y
China International Capital Corporation Limited UCL uCloudlink Group Inc. 13G 7.79% 2y
RA CAPITAL MANAGEMENT, L.P. TARA Protara Therapeutics, Inc. 13G 9.99% 2y
Rosalind Advisors, Inc. MDWD MediWound Ltd. 13G/A 6.92% 2y
Rosalind Advisors, Inc. SPRB Spruce Biosciences, Inc. 13G/A 3.67% 2y
Rosalind Advisors, Inc. CLRB Cellectar Biosciences, Inc. 13G/A 9.9% 2y
Rosalind Advisors, Inc. NSPR InspireMD, Inc. 13G/A 4.2% 2y
Rosalind Advisors, Inc. TRVI Trevi Therapeutics, Inc. 13G/A 1.34% 2y
Rosalind Advisors, Inc. MYO Myomo, Inc. 13G/A 9.9% 2y
Wayne W. Boos SLNH Soluna Holdings, Inc 13D/A 5.63% 2y
JEFF TOGHRAIE AXIL Axil Brands, Inc. 13D/A 50.6% 2y
Saba Capital Management, L.P. AFB Alliancebernstein National Municipal Income Fund 13D/A 9.24% 2y
Klaus Umek CRTO Criteo S.A. 13D/A 7.76% 2y
New Enterprise Associates 17, L.P. KRRO Korro Bio, Inc. 13D/A 11.8% 2y
MILLENNIUM MANAGEMENT LLC VERU Veru Inc. 13G 5.2% 2y
Deerfield Management Company, L.P. CGEM Cullinan Therapeutics, Inc. 13G 5.71% 2y
Scott Kapnick MDIA Mediaco Holding Inc. 13D 18.4% 2y
Samuel Wu OIO OIO Group 13D 43.48% 2y
Fosun International Ltd AMRX Amneal Pharmaceuticals, Inc. 13G/A 3% 2y
McBey Robert G ATCH AtlasClear Holdings, Inc. 13D 7.7% 2y
Relative Value Partners Group, LLC CCIF Carlyle Credit Income Fund 13G/A 0.13% 2y
Chemung Canal Trust Company E.I. No. CHMG Chemung Financial Corp 13G/A 7.04% 2y
Coliseum Capital Management, LLC GIL Gildan Activewear Inc. 13D/A 5.9% 2y
GAMCO INVESTORS, INC. ET AL MLI Mueller Industries Inc 13D/A 3.14% 2y
Saba Capital Management, L.P. SBI Western Asset Intermediate Muni Fund Inc. 13D/A 4.79% 2y
BAKER BROS. ADVISORS LP TCRX TScan Therapeutics, Inc. 13D/A 6.1% 2y
Findell Capital Partners LP OPRT Oportun Financial Corp 13D/A 8.5% 2y
AIMS Asset Management Sdn Bhd USAU U.S. Gold Corp. 13G/A 8.1% 2y
MILLENNIUM MANAGEMENT LLC SMTC Semtech Corp 13G 5.3% 2y
Blufire Capital Limited FHLT Future Health ESG Corp. Common stock 13D 50.88% 2y
Divisadero Street Capital Management, LP INGN Inogen Inc 13G 5.9% 2y
Rory Wallace BNED Barnes & Noble Education, Inc. 13D/A 9.7% 2y
BROWN ADVISORY INC BELFA Bel Fuse Inc 13G 6.7% 2y
Emerald Bioventures, LLC AVTX Avalo Therapeutics, Inc. 13G 5.6% 2y
Avoro Capital Advisors LLC SYRE Spyre Therapeutics, Inc. 13G/A 5.1% 2y
DNX III, LLC PARA Parabolic Technologies, Inc. 13G 6.97% 2y
Ned L. Sherwood BRN Barnwell Industries Inc 13D/A 29% 2y